VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Amarin Corp PLC Executive Compensation (FY25)

AMRN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Aaron Berg
Latest say-on-pay support
=
May 13, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Amarin Corp PLC brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 15, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Amarin Corp PLC brief$500Get the executive brief
Velarion Intel, one year, every company
254 figures on this page: 243 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Aaron Berg: $3,277,385 → $3,540,366 (8.0% higher)
Say-on-pay support: 71.1% → 51.9% (19.2 points lower)
CEO pay ratio: 21:1 → 11:1 (47.6% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Amarin Corp PLC's chief executive and what were they paid?
Aaron Berg, President and Chief Executive Officer, received $3,540,366 in total compensation for fiscal 2025. Berg's total was 8.0% higher than the $3,277,385 reported for fiscal 2024.
What was Amarin Corp PLC's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 51.9% of votes cast for or against in favor at the meeting held May 13, 2026.
Which companies are in Amarin Corp PLC's peer group?
The disclosed peer group names Coherus BioSciences, Inc., Collegium Pharmaceutical, Inc., Esperion Therapeutics, Inc., Evolus, Inc. and Harrow, Inc., among others.
What is Amarin Corp PLC's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 11:1, against median employee compensation of $326,639.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Karim Mikhail
Former President and Chief Executive Officer(1)
Departed during or after this year
◇—◇◇◇—◇◇
Jason Marks
Executive Vice President, Chief Legal and Compliance Officer & Corporate Secretary(4)
◇◇◇◇——◇◇
Steven Ketchum
Chief Scientific Officer
◇—◇◇◇—◇◇
Michael Kalb
Senior Vice President and Chief Financial Officer, Assistant Secretary(3)
◇—◇◇◇—◇◇
Aaron Berg
Senior Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
Thomas Reilly
Chief Financial Officer and Secretary(2)
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Karim Mikhail
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Aaron Berg
Executive Vice President, and President, U.S.
◇◇◇◇◇—◇◇
Steven Ketchum
Executive Vice President, President of Research and Development and Chief Scientific Officer
◇◇◇◇◇—◇◇
Thomas Reilly
Executive Vice President, Chief Financial Officer and Global Head of HR
◇◇◇◇◇—◇◇
Patrick Holt
President and Chief Executive Officer
◇——◇——◇◇
Jonathan Provoost
Executive Vice President, Chief Legal & Compliance Officer and Secretary
◇◇—◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Aaron Berg
President and Chief Executive Officer
◇◇◇◇——◇◇
Steven Ketchum
Executive Vice President, President of Research and Development and Chief Scientific Officer
◇◇◇◇◇—◇◇
Jonathan Provoost
Executive Vice President, Chief Legal & Compliance Officer and Secretary
◇———◇—◇◇
Peter Fishman
Senior Vice President, Chief Financial Officer
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Aaron Berg
President and Chief Executive Officer
◇◇◇◇◇—◇◇
Steven Ketchum
Executive Vice President, President of Research and Development and Chief Scientific Officer
◇◇◇◇◇—◇◇
David Keenan
Executive Vice President, Chief Operating Officer
◇◇◇◇◇—◇◇
Jonathan Provoost
Executive Vice President, Chief Legal & Compliance Officer and Secretary
◇◇◇◇◇—◇◇
Peter Fishman
Senior Vice President, Chief Financial Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Aaron D. BergOPTION◇——◇—◇◇
David P. KeenanOPTION◇——◇—◇◇
Jonathan N. ProvoostOPTION◇——◇—◇◇
Peter L. FishmanOPTION◇——◇—◇◇
Steven B. KetchumOPTION◇——◇—◇◇
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Aaron BergOption◇—◇6/26/2035
Option◇—◇2/1/2034
Option◇—◇2/21/2033
Option◇—◇2/4/2032
Jonathan ProvoostOption◇—◇1/10/2035
Option◇—◇11/15/2033
Steven KetchumOption◇—◇1/10/2035
Option◇—◇2/1/2034
Option◇—◇2/21/2033
Option◇—◇2/4/2032
David KeenanOption◇—◇1/10/2035
Option◇—◇2/1/2034
Option◇—◇2/21/2033
Option◇—◇6/1/2032
Peter FishmanOption◇—◇1/10/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Odysseas Kostas
Board chair
◇—————◇
Keith L. Horn
◇—————◇
Diane E. Sullivan
◇—————◇
Louis Sterling III
◇—————◇
Patrice Bonfiglio
◇—————◇
Paul Cohen
◇—————◇
Oliver O'Connor
◇—————◇
Michael Torok
◇—————◇
Mark DiPaolo
◇—————◇
Aaron D. Berg served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options and RSUs.
Stock ownership guideline: Director Stock Ownership Guidelines 73

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Coherus BioSciences, Inc. CHRS
  • Collegium Pharmaceutical, Inc. COLL
  • Esperion Therapeutics, Inc. ESPR
  • Evolus, Inc. EOLS
  • Harrow, Inc. HROW
  • Heron Therapeutics, Inc. HRTX
  • Innoviva, Inc. INVA
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Karyopharm Therapeutics, Inc. KPTI
  • MacroGenics, Inc. MGNX
  • Puma Biotechnology, Inc. PBYI
  • Revance Therapeutics Inc. RVNC
  • Rigel Pharmaceuticals Inc. RIGL
  • Travere Therapeutics, Inc. TVTX
  • Vanda Pharmaceuticals Inc. VNDA
  • Xeris Biopharma Holdings Inc. XERS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 13, 2026=◇◇◇
2024May 13, 2025=◇◇◇
2023April 18, 2024=◇◇◇
2022July 21, 2023=◇◇◇
2021June 27, 2022=◇◇◇
2020June 14, 2021=◇◇◇
2019July 13, 2020=◇◇◇
2018May 20, 2019=◇◇◇
2017May 14, 2018=◇◇◇
2016May 15, 2017=◇◇◇
2015July 11, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Aaron Berg (President and Chief Executive Officer), FY2025 total compensation $3,540,366 (base salary $725,667) [exec_comp, SEC accession 0001193125-26-151417, filed 2026-04-10]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Amarin Corp PLC files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Amarin Corp PLC disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amarin Corp PLC sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Amarin Corp PLC recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Amarin Corp PLC's disclosed peer group is defensible, who names Amarin Corp PLC back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
254 figures on this page: 243 cited to the filing that reported them, 11 calculated from figures it prints.
243 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-224771
  2. 0001193125-26-151417
    2025 Summary Compensation Table · Chief Executive Officer Pay Ratio · Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025 · Non-Employee Director Compensation · and 1 more section
  3. 0000950170-25-072817
  4. 0000950170-25-052674
    Summary Compensation Table
  5. 0000950170-24-046290
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-024353
    2023 Summary Compensation Table
  7. 0001193125-23-192541
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-23-154694
    2022 Summary Compensation Table
  9. 0001193125-22-186302
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-21-190656
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-20-192691
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-19-155481
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-18-168093
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-17-175994
    Item 5.07 Submission of Matters to a Vote of Security Holders
  15. 0001193125-16-648264
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amarin Corp PLC executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AMRN (accessed 2026).
Short form: data: Velarion

The Amarin Corp PLC brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amarin Corp PLC and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Amarin Corp PLC discloses

The companies named in AMRN's own disclosed peer group.

Coherus BioSciences, Inc.Collegium Pharmaceutical, Inc.Esperion Therapeutics, Inc.Evolus, Inc.Harrow, Inc.Heron Therapeutics, Inc.Innoviva, Inc.Ironwood Pharmaceuticals, Inc.Karyopharm Therapeutics, Inc.MacroGenics, Inc.Puma Biotechnology, Inc.Revance Therapeutics Inc.Rigel Pharmaceuticals Inc.Travere Therapeutics, Inc.Vanda Pharmaceuticals Inc.Xeris Biopharma Holdings Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy